Mutations in BRCA2 and taxane resistance in prostate cancer

Mutations in BRCA2 and taxane resistance in prostate cancer

Abstract Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-thre...

Full description

Saved in:
Bibliographic Details
Main Authors: Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A. Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich, Stefan Duensing
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/b15be919d5ff42faabf1b34d60384950
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items